Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.